Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis

Abstract This retrospective study aimed to identify predictors for the development of palbociclib-induced neutropenia. This study retrospectively analysed 78 breast cancer patients who had received palbociclib at our hospital between January 2018 and May 2020. For the regression analysis of factors...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yuko Kanbayashi, Koichi Sakaguchi, Takeshi Ishikawa, Koichi Takayama, Tetsuya Taguchi
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/7e65446849354672bb53b9a0f067b4e2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7e65446849354672bb53b9a0f067b4e2
record_format dspace
spelling oai:doaj.org-article:7e65446849354672bb53b9a0f067b4e22021-12-02T16:56:43ZPredictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis10.1038/s41598-021-99504-52045-2322https://doaj.org/article/7e65446849354672bb53b9a0f067b4e22021-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-99504-5https://doaj.org/toc/2045-2322Abstract This retrospective study aimed to identify predictors for the development of palbociclib-induced neutropenia. This study retrospectively analysed 78 breast cancer patients who had received palbociclib at our hospital between January 2018 and May 2020. For the regression analysis of factors associated with palbociclib-induced neutropenia, variables were extracted manually from medical charts. The level of palbociclib-induced neutropenia was evaluated using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 5). Multivariate ordered logistic regression analysis was performed to identify predictors for the development of neutropenia. Optimal cut-off thresholds were determined using receiver operating characteristic (ROC) analysis. Values of P < 0.05 (2-tailed) were considered significant. Significant factors identified included concomitant use of statin (odds ratio [OR] = 0.104, 95% confidence interval [CI] = 0.018–0.598; P = 0.011) and body mass index (BMI) (OR = 1.118, 95% CI = 1.007–1.241; P = 0.037). ROC analysis revealed that neutropenia (grade 4) was more likely to occur with a BMI ≥ 22.3 kg/m2. In conclusion, no concomitant use of statins and high BMI were identified as significant predictors for the development of palbociclib-induced neutropenia.Yuko KanbayashiKoichi SakaguchiTakeshi IshikawaKoichi TakayamaTetsuya TaguchiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-5 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Yuko Kanbayashi
Koichi Sakaguchi
Takeshi Ishikawa
Koichi Takayama
Tetsuya Taguchi
Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
description Abstract This retrospective study aimed to identify predictors for the development of palbociclib-induced neutropenia. This study retrospectively analysed 78 breast cancer patients who had received palbociclib at our hospital between January 2018 and May 2020. For the regression analysis of factors associated with palbociclib-induced neutropenia, variables were extracted manually from medical charts. The level of palbociclib-induced neutropenia was evaluated using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 5). Multivariate ordered logistic regression analysis was performed to identify predictors for the development of neutropenia. Optimal cut-off thresholds were determined using receiver operating characteristic (ROC) analysis. Values of P < 0.05 (2-tailed) were considered significant. Significant factors identified included concomitant use of statin (odds ratio [OR] = 0.104, 95% confidence interval [CI] = 0.018–0.598; P = 0.011) and body mass index (BMI) (OR = 1.118, 95% CI = 1.007–1.241; P = 0.037). ROC analysis revealed that neutropenia (grade 4) was more likely to occur with a BMI ≥ 22.3 kg/m2. In conclusion, no concomitant use of statins and high BMI were identified as significant predictors for the development of palbociclib-induced neutropenia.
format article
author Yuko Kanbayashi
Koichi Sakaguchi
Takeshi Ishikawa
Koichi Takayama
Tetsuya Taguchi
author_facet Yuko Kanbayashi
Koichi Sakaguchi
Takeshi Ishikawa
Koichi Takayama
Tetsuya Taguchi
author_sort Yuko Kanbayashi
title Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
title_short Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
title_full Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
title_fullStr Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
title_full_unstemmed Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
title_sort predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/7e65446849354672bb53b9a0f067b4e2
work_keys_str_mv AT yukokanbayashi predictorsfordevelopmentofpalbociclibinducedneutropeniainbreastcancerpatientsasdeterminedbyorderedlogisticregressionanalysis
AT koichisakaguchi predictorsfordevelopmentofpalbociclibinducedneutropeniainbreastcancerpatientsasdeterminedbyorderedlogisticregressionanalysis
AT takeshiishikawa predictorsfordevelopmentofpalbociclibinducedneutropeniainbreastcancerpatientsasdeterminedbyorderedlogisticregressionanalysis
AT koichitakayama predictorsfordevelopmentofpalbociclibinducedneutropeniainbreastcancerpatientsasdeterminedbyorderedlogisticregressionanalysis
AT tetsuyataguchi predictorsfordevelopmentofpalbociclibinducedneutropeniainbreastcancerpatientsasdeterminedbyorderedlogisticregressionanalysis
_version_ 1718382748588048384